Regeneron Pharmaceuticals OPTIMA Trial Posted on

Learn more about the OPTIMA trial that may be of interest to you is a web-based resource that provides patients, their family members, health care professionals, researchers and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. The site is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in the United States.

Information on is provided and updated by the sponsor or principal investigator of the clinical study. Studies are generally submitted to the site (that is, registered) when they begin, and the information on the site is updated throughout the study.

Regeneron recently submitted the OPTIMA trial to The trial is a phase III study to examine the safety and efficacy of garetosmab versus placebo administered intravenously (IV) in adult participants with fibrodysplasia ossificans progressiva (FOP).

The randomized, parallel assignment trial will recruit 66 participants ages 18 and older. The length of the trial is 56 weeks.

Trial locations have not yet been announced. The estimated study start date is currently listed as July 14, 2022.

Every clinical trial includes inclusion and exclusion criteria. Inclusion criteria are the characteristics that a person must have in order to participate in a trial. Exclusion criteria are the reasons why a person cannot participate in a trial. The initial OPTIMA inclusion/exclusion criteria are listed below. To see full details of the trial, click here.

Inclusion Criteria:

  1. Male or female 18 years or older at screening
  2. Clinical diagnosis of fibrodysplasia ossificans progressiva (FOP) [(based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive heterotopic ossification (HO)]
  3. Confirmation of FOP diagnosis with documentation of Type I activin A receptor (ACVR1) FOP causing mutation
  4. FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, or other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of HO lesions (increase in size or number of HO lesions) with/without being associated with flare-up episodes
  5. Willing and able to undergo CT imaging procedures and other procedures as defined in the protocol

Exclusion Criteria:

  1. Cumulative Analog Joint Involvement Scale (CAJIS)* score at screening >19
  2. Participant has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study
  3. Previous history or diagnosis of cancer
  4. Severely impaired renal function defined as estimated glomerular filtration rate <30 milliliter per minute (mL/min) (/1.73 m^2 calculated by the Modification of Diet in Renal Disease equation
  5. Uncontrolled diabetes defined as hemoglobin A1C (HbA1c) >9% at screening
  6. History of poorly controlled hypertension as defined, as defined by:
    1. Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg at the screening visit
    2. Systolic blood pressure of 160 mm Hg to 179 mm Hg or diastolic blood pressure of 100 mm Hg to 109 mm Hg at the screening visit, AND a history of end-organ damage (including history of left-ventricular hypertrophy, heart failure, angina, myocardial infarction, stroke, transient ischemic attack, peripheral arterial disease, end-stage renal disease, and moderate-to-advanced retinopathy
  7. Known history of cerebral vascular malformation
  8. Cardiovascular conditions such as New York Heart Association class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia
  9. History of severe respiratory compromise requiring oxygen, respiratory support (eg, bilevel positive airway pressure [biPAP] or continuous positive airway pressure [CPAP]), or a history of aspiration pneumonia requiring hospitalization
  10. Prior use in the past year and concomitant use of bisphosphonates
  11. Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures (eg, collection of blood or tissue samples).
  12. Treatment with another investigational drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer
  13. Pregnant or breastfeeding women
  14. Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception
  15. Male patients with WOCBP partners who are not willing to use condoms with WOCBP partners to prevent potential fetal exposure

Note: Other protocol defined Inclusion/Exclusion Criteria apply 

* The cumulative analogue joint involvement scale (CAJIS) is a simple, rapidly-administered functional mobility assessment of FOP performed by a physician. The CAJIS score provides an accurate and reproducible snapshot of total body and regional mobility burden in FOP.

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter